Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Adalimumab × Head & Neck × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Genitourinary 1 Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Cisplatin 361 Radiotherapy 213 Radiotherapy, Intensity-Modulated 158 Cetuximab 154 Docetaxel 145 pembrolizumab 130 Carboplatin 107 Fluorouracil 103 Paclitaxel 83 Gemcitabine 73 Nivolumab 71 Radiation 66 Surveys and Questionnaires 62 toripalimab 60 Drug Therapy 59 Magnetic Resonance Spectroscopy 56 Surgical Procedures, Operative 54 Blood Specimen Collection 46 Capecitabine 45 Biopsy 43 durvalumab 38 camrelizumab 37 Chemoradiotherapy 37 Standard of Care 33 Radiosurgery 31 apatinib 30 tislelizumab 28 nimotuzumab 28 130-nm albumin-bound paclitaxel 27 Erlotinib Hydrochloride 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02516774 2016-01-26

TAM-RT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡